NASDAQ · MOVE
Corvex, Inc.
$7.22-$0.09 (-1.23%)
Corvex, Inc.’s quoted price sits in the lower half of its reported 52-week range, 79.29% below the high.
Loading market information…
NASDAQ · NDRA · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
ENDRA Life Sciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 29.78% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
ENDRA Life Sciences Inc.’s next earnings report is currently expected on Nov 13, 2026, with estimated earnings per share of -$0.84. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow ENDRA Life Sciences Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, which operates by emitting sound waves that echo off internal body components such as tissues, organs, and blood. This innovation is utilized in managing nonalcoholic fatty liver disease, meticulously monitoring temperature during thermoablative surgical procedures, detailed vascular imaging, and assessing tissue perfusion. Furthermore, ENDRA offers other diagnostic imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), and conventional ultrasound. These instruments empower physicians to visualize internal anatomy, aiding in treatment guidance and the identification of various medical conditions like bone fractures, cancerous growths, indicators of heart disease, or internal bleeding. The company also maintains a research collaboration agreement with General Electric Company. Established in 2007, ENDRA Life Sciences Inc. is headquartered in Ann Arbor, Michigan.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:08 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00 |
| Q4 2024 | Mar 31, 2025 | -$9.40-129.27% vs estimate | $0.00-100.0% vs estimate |
|---|
| Q3 2024 | Nov 15, 2024 | -$5.85+90.61% vs estimate | $0.00-100.0% vs estimate |
|---|
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$7.22-$0.09 (-1.23%)
Corvex, Inc.’s quoted price sits in the lower half of its reported 52-week range, 79.29% below the high.
$3.61+$0.24 (+7.12%)
HeartSciences Inc.’s quoted price sits in the upper half of its reported 52-week range, 31.24% below the high.
$0.83-$0.09 (-9.79%)
Bio Green Med Solution, Inc.’s quoted price sits in the lower half of its reported 52-week range, 70.36% below the high.
$0.79-$0.08 (-9.35%)
iSpecimen Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.6% below the high.
$1.90+$0.02 (+1.06%)
NanoVibronix, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.83% below the high.
$0.39-$0.00 (-0.94%)
Bone Biologics Corporation’s quoted price sits in the lower half of its reported 52-week range, 83.75% below the high.
$0.16$0.00 (0.0%)
BNB Plus Corp.’s quoted price sits in the lower half of its reported 52-week range, 97.72% below the high.
$0.31+$0.01 (+2.64%)
Venus Concept Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.59% below the high.
